The treatment of hepatic metastases in colorectal carcinoma

American Surgeon

Volumn 72, Issue 6, 2006, Pages 466-473

  Lewis, Angela M ^a   Martin II, Robert C G ^a,b  

^a University of Louisville School of Medicine   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; BEVACIZUMAB; CAPECITABINE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MONOCLONAL ANTIBODY; OXALIPLATIN;

ADJUVANT THERAPY; ALOPECIA; BONE MARROW SUPPRESSION; CLINICAL TRIAL; COLORECTAL CARCINOMA; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CRYOTHERAPY; DIARRHEA; DISEASE MANAGEMENT; DRUG POTENTIATION; HUMAN; LIVER METASTASIS; RADIODIAGNOSIS; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL; REVIEW; SENSORY NEUROPATHY; SURGICAL TECHNIQUE; CATHETER ABLATION; COLORECTAL TUMOR; LAPAROSCOPY; LIVER TUMOR; METASTASIS; MULTIMODALITY CANCER THERAPY; PATHOLOGY;

CATHETER ABLATION; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; HUMANS; LAPAROSCOPY; LIVER NEOPLASMS;

EID: 33746522433     PISSN: 00031348     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. Bakalakos EA, Kim JA, Young DC, Martin EW Jr. Determinants of survival following hepatic resection for metastatic colorectal cancer. World J Surg 1998;22:399-404.
2. Jenkins LT, Millikan KW, Bines SD, et al. Hepatic resection for metastatic colorectal cancer. Am Surg 1997;63:605-10.
3. Fong Y, Cohen AM, Fortner JG, et al. Liver resection for colorectal metastases. J Clin Oncol 1997;15:938-46.
4. Jamison RL, Donohue JH, Nagorney DM, et al. Hepatic resection for metastatic colorectal cancer results in cure for some patients. Arch Surg 1997;132:505-10.
5. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin 2000;50:7-33.
6. Gilbert HA, Kagan AR. Metastases: Incidence, detection, and evaluation without histologic confirmation. Weiss 1976;L:385-405.
7. Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999;230:309-18.
8. Gonen M, Hummer A, Zervoudakis A, et al. Thymidylate synthase expression in hepatic tumors is a predictor of survival and progression in patients with resectable metastatic colorectal cancer. J Clin Oncol 2003;21:406-12.
9. Nagakura S, Shirai Y, Yokoyama N, et al. Major hepatic resection reduces the probability of intrahepatic recurrences following resection of colorectal carcinoma liver metastases. Hepatogastroenterology 2003;50:779-83.
10. Yan DB, Clingan P, Morris DL. Hepatic cryotherapy and regional chemotherapy with or without resection for liver metastases from colorectal carcinoma: how many are too many? Cancer 2003;98:320-30.
11. Mauchley DC, Lynge DC, Langdale LA, et al. Clinical utility and cost-effectiveness of routine preoperative computed tomography scanning in patients with colon cancer. Am J Surg 2005;189:512-7.
12. Shoup M, Gonen M, D'Angelica M, et al. Volumetric analysis predicts hepatic dysfunction in patients undergoing major liver resection. J Gastrointest Surg 2003;7:325-30.
13. Abdalla EK, Barnett CC, Doherty D, et al. Extended hepatectomy in patients with hepatobiliary malignancies with and without preoperative portal vein embolization. Arch Surg 2002;137:675-80.
14. Scheele J, Altendorf-Hofmann A. Resection of colorectal liver metastases. Langenbecks Arch Surg 1999;384:313-27.
15. Ruers TJ, Langenhoff BS, Neeleman N, et al. Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study. J Clin Oncol 2002;20:388-95.
16. Strasberg SM, Dehdashti F, Siegel BA, et al. Survival of patients evaluated by FDG-PET before hepatic resection for metastatic colorectal carcinoma: a prospective database study. Ann Surg 2001;233:293-9.
17. Schussler-Fiorenza CM, Mahvi DM, Niederhuber J, et al. Clinical risk score correlates with yield of PET scan in patients with colorectal hepatic metastases. J Gastrointest Surg 2004;8:150-7.
18. Rodgers MS, Collinson R, Desai S, et al. Risk of dissemination with biopsy of colorectal liver metastases. Dis Colon Rectum 2003;46:454-8.
19. Jones OM, Rees M, John TG, et al. Biopsy of resectable colorectal liver metastases causes tumour dissemination and adversely affects survival after liver resection. Br J Surg 2005;92:1165-8.
20. Thaler K, Kanneganti S, Khajanchee Y, et al. The evolving role of staging laparoscopy in the treatment of colorectal hepatic metastasis. Arch Surg 2005;140:727-34.
21. Lo CM, Lai EC, Liu CL, et al. Laparoscopy and laparoscopic ultrasonography avoid exploratory laparotomy in patients with hepatocellular carcinoma. Ann Surg 1998;227:527-32.
22. Callery MP, Strasberg SM, Doherty GM, et al. Staging laparoscopy with laparoscopic ultrasonography: optimizing resectability in hepatobiliary and pancreatic malignancy. J Am Coll Surg 1997;185:33-9.
23. Gervaz P, Pak-art R, Nivatvongs S, et al. Colorectal adenocarcinoma in cirrhotic patients. J Am Coll Surg 2003;196:874-9.
24. Kemeny N, Huang Y, Cohen AM, et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 1999;341:2039-48.
25. Lorenz M, Staib-Sebler E, Gog C, et al. Prospective pilot study of neoadjuvant chemotherapy with 5-fluorouracil, folinic acid and oxaliplatin in resectable liver metastases of colorectal cancer. Analysis of 42 neoadjuvant chemotherapies. Zentralbl Chir 2003;128:87-94.
26. Onaitis M, Morse M, Hurwitz H, et al. Adjuvant hepatic arterial chemotherapy following metastasectomy in patients with isolated liver metastases. Ann Surg 2003;237:782-8.
27. Tanaka K, Adam R, Shimada H, et al. Role of neoadjuvant chemotherapy in the treatment of multiple colorectal metastases to the liver. Br J Surg 2003;90:963-9.
28. Teh CS, Ooi LL. Hepatic resection for colorectal metastases to the liver: The National Cancer Centre/Singapore General Hospital experience. Ann Acad Med Singapore 2003;32:196-204.
29. Abdalla EK, Vauthey JN, Ellis LM, et al. Recurrence and outcomes following hepatic resection, radio frequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 2004;239:818-25.
30. Chua HK, Sondenaa K, Tsiotos GG, et al. Concurrent vs. staged colectomy and hepatectomy for primary colorectal cancer with synchronous hepatic metastases. Dis Colon Rectum 2004;47:1310-6.
31. Laurent C, Sa CA, Rullier E, et al. Impact of microscopic hepatic lymph node involvement on survival after resection of colorectal liver metastasis. J Am Coll Surg 2004;198:884-91.
32. Nagashima I, Takada T, Matsuda K, et al. A new scoring system to classify patients with colorectal liver metastases: proposal of criteria to select candidates for hepatic resection. J Hepatobiliary Pancreat Surg 2004;11:79-83.
33. Shimada H, Tanaka K, Masui H, et al. Results of surgical treatment for multiple (≥5 nodules) bi-lobar hepatic metastases from colorectal cancer. Langenbecks Arch Surg 2004;389:114-21.
34. Tanaka K, Shimada H, Ohta M, et al. Procedures of choice for resection of primary and recurrent liver metastases from colorectal cancer. World J Surg 2004;28:482-7.
35. Tocchi A, Mazzoni G, Brozzetti S, et al. Hepatic resection in stage IV colorectal cancer: prognostic predictors of outcome. Int J Colorectal Dis 2004;19:580-5.
36. Couinaud C. Le Foie: Etudes Anatomiques et Chirurgicales. Paris: Masson & Cie, 1957.
37. Martin RCG, Paty P, Fong Y, et al. Simultaneous Liver and Colorectal Resections are Safe for Synchronous Colorectal Liver Metastasis, J Am Coll Surg 2003;197:233-41.
38. Nordlinger B, Quilichini MA, Parc R, et al. Hepatic resection for colorectal liver metastases. Influence on survival of preoperative factors and surgery for recurrences in 80 patients. Ann Surg 1987;205:256-63.
39. Stadler J, Holscher AH, Adolf J. Intraoperative ultrasonographic detection of occult liver metastases in colorectal cancer. Surg Endosc 1991;5:36-40.
40. Roh MS. Hepatic resection for colorectal liver metastases. Hematol Oncol Clin North Am 1989;3:171-81.
41. Kokudo N, Miki Y, Sugai S, et al. Genetic and histological assessment of surgical margins in resected liver metastases from colorectal carcinoma: minimum surgical margins for successful resection. Arch Surg 2002;137:833-40.
42. Melendez JA, Arslan V, Fischer ME, et al. Perioperative outcomes of major hepatic resections under low central venous pressure anesthesia: blood loss, blood transfusion, and the risk of postoperative renal dysfunction. J Am Coll Surg 1998;187:620-5.
43. Kooby DA, Jarnagin WR. Surgical management of hepatic malignancy. Cancer Invest 2004;22:283-303.
44. Elias D, Detroz B, Lasser P, et al. Is simultaneous hepatectomy and intestinal anastomosis safe? Am J Surg 1995;169:254-60.
45. Fujita S, Akasu T, Moriya Y. Resection of synchronous liver metastases from colorectal cancer. Jpn J Clin Oncol 2000;30:7-11.
46. Nakamura S, Yokoi Y, Suzuki S, et al. Results of extensive surgery for liver metastases in colorectal carcinoma. Br J Surg 1992;79:35-8.
47. Gough DB, Donohue JH, Trastek VA, Nagorney DM. Resection of hepatic and pulmonary metastases in patients with colorectal cancer. Br J Surg 1994;81:94-6.
48. Regnard JF, Grunenwald D, Spaggiari L, et al. Surgical treatment of hepatic and pulmonary metastases from colorectal cancers. Ann Thorac Surg 1998;66:214-8.
49. Ambiru S, Miyazaki M, Ito H, et al. Resection of hepatic and pulmonary metastases in patients with colorectal carcinoma. Cancer 1998;82:274-8.
50. Murata S, Moriya Y, Akasu T, et al. Resection of both hepatic and pulmonary metastases in patients with colorectal carcinoma. Cancer 1998;83:1086-93.
51. Rossi S, Di Stasi M, Buscarini E, et al. Percutaneous RF interstitial thermal ablation in the treatment of hepatic cancer. AJR Am J Roentgenol 1996;167:759-68.
52. Curley SA, Izzo F, Delrio P, et al. Radio frequency ablation of unresectable primary and metastatic hepatic malignancies: results in 123 patients. Ann Surg 1999;230:1-8.
53. Wood TF, Rose DM, Chung M, et al. Radio frequency ablation of 231 unresectable hepatic tumors: indications, limitations, and complications. Ann Surg Oncol 2000;7:593-600.
54. Siperstein A, Garland A, Engle K, et al. Local recurrence after laparoscopic radio frequency thermal ablation of hepatic tumors. Ann Surg Oncol 2000;7:106-13.
55. De Baere T, Elias D, Dromain C, et al. Radio frequency ablation of 100 hepatic metastases with a mean follow-up of more than 1 year. AJR Am J Roentgenol 2000;175:1619-25.
56. Machi J. Radio frequency ablation for multiple hepatic metastases. Ann Surg Oncol 2001;8:379-80.
57. Curley SA, Marra P, Beaty K, et al. Early and late complications after radio frequency ablation of malignant liver tumors in 608 patients. Ann Surg 2004;239:450-8.
58. Bilchik AJ, Rose DM, Allegra DP, et al. Radio frequency ablation: a minimally invasive technique with multiple applications. Cancer J Sci Am 1999;5:356-61.
59. Pearson AS, Izzo F, Fleming RY, et al. Intraoperative radio frequency ablation or cryoablation for hepatic malignancies. Am J Surg 1999;178:592-9.
60. Meta-Analysis Group in Cancer. Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J Natl Cancer Inst 1996;88:252-8.
61. Martin RCG, Edwards MJ, McMasters KM. Morbidity of Adjuvant Hepatic Arterial Infusion Pump Chemotherapy in the Management of Colorectal Cancer Metastatic to the Liver. Am J Surg 2004;188:714-21.
62. Gray B, Van Hazel G, Hope M, et al. Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol 2001;12:1711-20.
63. Van Hazel G, Blackwell A, Anderson J, et al. Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol 2004;88:78-85.
64. Lim L, Gibbs P, Yip D, et al. Prospective study of treatment with selective internal radiation therapy spheres in patients with unresectable primary or secondary hepatic malignancies. Intern Med J 2005;35:222-7.
65. Dawson LA, Lawrence TS. The role of radiotherapy in the treatment of liver metastases. Cancer J 2004;10:139-44.
66. Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004;240:644-57.
67. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) Investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995;345:939-44.
68. Moertel CG, Fleming TR, Macdonald JS, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995;122:321-6.
69. Haller DG, Lefkopoulou M, Macdonald JS, Mayer RS. Some considerations concerning the dose and schedule of 5FU and leucovorin: toxicities of two dose schedules from the intergroup colon adjuvant trial (INT-0089). Adv Exp Med Biol 1993;339:51-4.
70. Haller DG, Catalano PJ, MacDonald JS. Flourouracil (FU), leucovorin (LV), and levamisole (LEV) adjuvant therapy for colon cancer: five year report of INT-0089. Proc Am Soc Clin Oncol 1998;17:982, 256a.
71. Gill S, Loprinzi CL, Sargent DJ, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 2004;22:1797-806.
72. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-47.
73. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45.
74. Ellis LM, Curley SA, Grothey A. Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab. J Clin Oncol 2005;23:4853-5.